TY - STD TI - Organization WH. Global hepatitis report 2017: World Health Organization; 2017. ID - ref1 ER - TY - JOUR PY - 2017 DA - 2017// TI - EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection JO - J Hepatol VL - 67 UR - https://doi.org/10.1016/j.jhep.2017.03.021 DO - 10.1016/j.jhep.2017.03.021 ID - ref2 ER - TY - JOUR AU - Sherman, M. AU - Shafran, S. AU - Burak, K. AU - Doucette, K. AU - Wong, W. AU - Girgrah, N. PY - 2007 DA - 2007// TI - Management of chronic hepatitis B: consensus guidelines JO - Can J Gastroenterol VL - 21 Suppl C UR - https://doi.org/10.1155/2007/910831 DO - 10.1155/2007/910831 ID - Sherman2007 ER - TY - JOUR AU - Ghany, M. G. AU - Doo, E. C. PY - 2009 DA - 2009// TI - Antiviral Resistance and hepatitis B therapy JO - Hepatology (Baltimore, Md). VL - 49 UR - https://doi.org/10.1002/hep.22900 DO - 10.1002/hep.22900 ID - Ghany2009 ER - TY - STD TI - Drugs@FDA: FDA Approved Drug Products: Tenofovir Alafenamide Fumarate [Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208464. Accessed 1 July 2018. UR - https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208464 ID - ref5 ER - TY - STD TI - Health Canada Drug Product Database [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed 1 July 2018. UR - https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html ID - ref6 ER - TY - JOUR AU - Liu, Y. AU - Corsa, A. AU - Buti, M. AU - Cathcart, A. AU - Flaherty, J. AU - Miller, M. PY - 2017 DA - 2017// TI - No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment JO - Journal of viral hepatitis. VL - 24 UR - https://doi.org/10.1111/jvh.12613 DO - 10.1111/jvh.12613 ID - Liu2017 ER - TY - JOUR AU - Sherman, M. AU - Lee, S. S. PY - 2011 DA - 2011// TI - Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change JO - Can J Gastroenterol. VL - 25 UR - https://doi.org/10.1155/2011/864046 DO - 10.1155/2011/864046 ID - Sherman2011 ER - TY - JOUR AU - Woo, G. AU - Tomlinson, G. AU - Nishikawa, Y. AU - Kowgier, M. AU - Sherman, M. AU - Wong, D. K. H. PY - 2010 DA - 2010// TI - Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses JO - Gastroenterology. VL - 139 UR - https://doi.org/10.1053/j.gastro.2010.06.042 DO - 10.1053/j.gastro.2010.06.042 ID - Woo2010 ER - TY - JOUR AU - Ismail, S. AU - Hafez, H. A. AU - Darweesh, S. K. AU - Kamal, K. H. AU - Esmat, G. PY - 2014 DA - 2014// TI - Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy JO - Ann Gastroenterol VL - 27 ID - Ismail2014 ER - TY - JOUR AU - Huang, Y. -. J. AU - Chang, C. -. S. AU - Peng, Y. -. C. AU - Yeh, H. -. Z. AU - Yang, S. -. S. PY - 2017 DA - 2017// TI - On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B JO - PLoS One. VL - 12 UR - https://doi.org/10.1371/journal.pone.0174046 DO - 10.1371/journal.pone.0174046 ID - Huang2017 ER - TY - JOUR AU - Ustianowski, A. AU - Arends, J. E. PY - 2015 DA - 2015// TI - Tenofovir: What we have learnt after 7.5 Million person-years of use JO - infectious diseases and therapy. VL - 4 UR - https://doi.org/10.1007/s40121-015-0070-1 DO - 10.1007/s40121-015-0070-1 ID - Ustianowski2015 ER - TY - BOOK AU - Wong, W. W. AU - Pechlivanoglou, P. AU - Erman, A. AU - Saeed, Y. AU - Younis, M. AU - Rayad, N. Z. PY - 2015 DA - 2015// TI - FINAL CENSORED REPORT: Treatment for chronic hepatitis B ID - Wong2015 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. AU - Mulrow, C. AU - Gotzsche, P. C. AU - Ioannidis, J. P. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration JO - BMJ. VL - 339 UR - https://doi.org/10.1136/bmj.b2700 DO - 10.1136/bmj.b2700 ID - Liberati2009 ER - TY - JOUR AU - Moher, D. AU - Shamseer, L. AU - Clarke, M. AU - Ghersi, D. AU - Liberati, A. AU - Petticrew, M. PY - 2015 DA - 2015// TI - Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement JO - Syst Rev. VL - 4 UR - https://doi.org/10.1186/2046-4053-4-1 DO - 10.1186/2046-4053-4-1 ID - Moher2015 ER - TY - STD TI - Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 The Cochrane Collaboration; [updated March 2011]. Available from: http://handbook-5-1.cochrane.org/. UR - http://handbook-5-1.cochrane.org/ ID - ref16 ER - TY - JOUR AU - Higgins, J. P. T. AU - Altman, D. G. AU - Gotzsche, P. C. AU - Juni, P. AU - Moher, D. AU - Oxman, A. D. AU - Savovic, J. AU - Schulz, K. F. AU - Weeks, L. AU - Sterne, J. A. C. PY - 2011 DA - 2011// TI - The Cochrane Collaboration's tool for assessing risk of bias in randomised trials JO - BMJ VL - 343 UR - https://doi.org/10.1136/bmj.d5928 DO - 10.1136/bmj.d5928 ID - Higgins2011 ER - TY - BOOK AU - Plummer, M. PY - 2003 DA - 2003// TI - JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling PB - Proceedings of the 3rd international workshop on distributed statistical computing CY - Vienna ID - Plummer2003 ER - TY - JOUR AU - Valkenhoef, G. AU - Lu, G. AU - Brock, B. AU - Hillege, H. AU - Ades, A. E. AU - Welton, N. J. PY - 2012 DA - 2012// TI - Automating network meta-analysis JO - Res Synth Methods. VL - 3 UR - https://doi.org/10.1002/jrsm.1054 DO - 10.1002/jrsm.1054 ID - Valkenhoef2012 ER - TY - JOUR AU - Brooks, S. P. AU - Gelman, A. PY - 1998 DA - 1998// TI - General methods for monitoring convergence of iterative simulations JO - Journal of computational and graphical statistics. VL - 7 ID - Brooks1998 ER - TY - JOUR AU - Dias, S. AU - Welton, N. AU - Caldwell, D. AU - Ades, A. PY - 2010 DA - 2010// TI - Checking consistency in mixed treatment comparison meta analysis JO - Statistics in medicine. VL - 29 UR - https://doi.org/10.1002/sim.3767 DO - 10.1002/sim.3767 ID - Dias2010 ER - TY - JOUR AU - Brouwer, W. P. AU - Xie, Q. AU - Sonneveld, M. J. AU - Zhang, N. AU - Zhang, Q. AU - Tabak, F. PY - 2015 DA - 2015// TI - Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) JO - Hepatology. VL - 61 UR - https://doi.org/10.1002/hep.27586 DO - 10.1002/hep.27586 ID - Brouwer2015 ER - TY - JOUR AU - Cao, Z. H. AU - Ma, L. N. AU - Zhang, H. W. AU - Liu, Y. L. AU - Chen, X. Y. PY - 2013 DA - 2013// TI - Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion JO - Journal of Digestive Diseases. VL - 14 UR - https://doi.org/10.1111/1751-2980.12065 DO - 10.1111/1751-2980.12065 ID - Cao2013 ER - TY - JOUR AU - Chan, H. L. AU - Heathcote, E. J. AU - Marcellin, P. AU - Lai, C. L. AU - Cho, M. AU - Moon, Y. M. PY - 2007 DA - 2007// TI - Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial JO - Ann Intern Med. VL - 147 UR - https://doi.org/10.7326/0003-4819-147-11-200712040-00183 DO - 10.7326/0003-4819-147-11-200712040-00183 ID - Chan2007 ER - TY - JOUR AU - Chan, H. L. AU - Fung, S. AU - Seto, W. K. AU - Chuang, W. -. L. AU - Chen, C. -. Y. AU - Kim, H. J. PY - 2016 DA - 2016// TI - Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial JO - The Lancet Gastroenterology & Hepatology. VL - 1 UR - https://doi.org/10.1016/S2468-1253(16)30024-3 DO - 10.1016/S2468-1253(16)30024-3 ID - Chan2016 ER - TY - JOUR AU - Chang, T. T. AU - Gish, R. G. AU - Man, R. AU - Gadano, A. AU - Sollano, J. AU - Chao, Y. C. PY - 2006 DA - 2006// TI - A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B JO - N Engl J Med. VL - 354 UR - https://doi.org/10.1056/NEJMoa051285 DO - 10.1056/NEJMoa051285 ID - Chang2006 ER - TY - JOUR AU - Dienstag, J. L. AU - Schiff, E. R. AU - Wright, T. L. AU - Perrillo, R. P. AU - Hann, H. W. AU - Goodman, Z. PY - 1999 DA - 1999// TI - Lamivudine as initial treatment for chronic hepatitis B in the United States JO - N Engl J Med. VL - 341 UR - https://doi.org/10.1056/NEJM199910213411702 DO - 10.1056/NEJM199910213411702 ID - Dienstag1999 ER - TY - STD TI - He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, et al. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clinics and research in hepatology and gastroenterology [Internet]. 2012; 36(6):[592-597 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/488/CN-00859488/frame.html. UR - http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/488/CN-00859488/frame.html ID - ref28 ER - TY - JOUR AU - Janssen, H. L. AU - Zonneveld, M. AU - Senturk, H. AU - Zeuzem, S. AU - Akarca, U. S. AU - Cakaloglu, Y. PY - 2005 DA - 2005// TI - Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial JO - Lancet. VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)17701-0 DO - 10.1016/S0140-6736(05)17701-0 ID - Janssen2005 ER - TY - STD TI - Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients. Hepatology Research. 2017. ID - ref30 ER - TY - JOUR AU - Lai, C. L. AU - Chien, R. N. AU - Leung, N. W. AU - Chang, T. T. AU - Guan, R. AU - Tai, D. I. PY - 1998 DA - 1998// TI - A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group JO - N Engl J Med. VL - 339 UR - https://doi.org/10.1056/NEJM199807093390201 DO - 10.1056/NEJM199807093390201 ID - Lai1998 ER - TY - JOUR AU - Lai, C. L. AU - Leung, N. AU - Teo, E. K. AU - Tong, M. AU - Wong, F. AU - Hann, H. W. PY - 2005 DA - 2005// TI - A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B JO - Gastroenterology. VL - 129 UR - https://doi.org/10.1016/j.gastro.2005.05.053 DO - 10.1016/j.gastro.2005.05.053 ID - Lai2005 ER - TY - JOUR AU - Lau, G. K. AU - Piratvisuth, T. AU - Luo, K. X. AU - Marcellin, P. AU - Thongsawat, S. AU - Cooksley, G. PY - 2005 DA - 2005// TI - Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B JO - N Engl J Med. VL - 352 UR - https://doi.org/10.1056/NEJMoa043470 DO - 10.1056/NEJMoa043470 ID - Lau2005 ER - TY - JOUR AU - Leung, N. AU - Peng, C. Y. AU - Hann, H. W. AU - Sollano, J. AU - Lao-Tan, J. AU - Hsu, C. W. PY - 2009 DA - 2009// TI - Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir JO - Hepatology. VL - 49 UR - https://doi.org/10.1002/hep.22658 DO - 10.1002/hep.22658 ID - Leung2009 ER - TY - JOUR AU - Liang, X. AU - Cheng, J. AU - Sun, Y. AU - Chen, X. AU - Li, T. AU - Wang, H. PY - 2015 DA - 2015// TI - Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients JO - Journal of gastroenterology and hepatology. VL - 30 UR - https://doi.org/10.1111/jgh.12835 DO - 10.1111/jgh.12835 ID - Liang2015 ER - TY - JOUR AU - Liu, Y. H. AU - Wu, T. AU - Sun, N. AU - Wang, G. L. AU - Yuan, J. Z. AU - Dai, Y. R. PY - 2014 DA - 2014// TI - Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study JO - Journal of Huazhong University of Science and Technology Medical Sciences. VL - 34 UR - https://doi.org/10.1007/s11596-014-1312-2 DO - 10.1007/s11596-014-1312-2 ID - Liu2014 ER - TY - JOUR AU - Marcellin, P. AU - Chang, T. T. AU - Lim, S. G. AU - Tong, M. J. AU - Sievert, W. AU - Shiffman, M. L. PY - 2003 DA - 2003// TI - Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B JO - N Engl J Med. VL - 348 UR - https://doi.org/10.1056/NEJMoa020681 DO - 10.1056/NEJMoa020681 ID - Marcellin2003 ER - TY - JOUR AU - Marcellin, P. AU - Ahn, S. H. AU - Ma, X. AU - Caruntu, F. A. AU - Tak, W. Y. AU - Elkashab, M. PY - 2016 DA - 2016// TI - Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2015.09.043 DO - 10.1053/j.gastro.2015.09.043 ID - Marcellin2016 ER - TY - JOUR AU - Ren, F. Y. AU - Piao, D. M. AU - Piao, X. X. PY - 2007 DA - 2007// TI - A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B JO - World J Gastroenterol. VL - 13 UR - https://doi.org/10.3748/wjg.v13.i31.4264 DO - 10.3748/wjg.v13.i31.4264 ID - Ren2007 ER - TY - JOUR AU - Sriprayoon, T. a. s. s. a. n. e. e. AU - Mahidol, C. h. u. l. a. b. h. o. r. n. AU - Ungtrakul, T. e. e. r. a. p. a. t. AU - Chun-on, P. a. t. t. r. a. AU - Soonklang, K. a. m. o. n. w. a. n. AU - Pongpun, W. a. n. v. i. s. a. AU - Laohapand, C. h. a. r. l. i. e. AU - Dechma, J. i. r. a. p. o. r. n. AU - Pothijaroen, C. h. a. r. i. n. t. h. i. p. AU - Auewarakul, C. h. i. r. a. y. u. AU - Tanwandee, T. a. w. e. s. a. k. PY - 2016 DA - 2016// TI - Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial JO - Hepatology Research VL - 47 UR - https://doi.org/10.1111/hepr.12743 DO - 10.1111/hepr.12743 ID - Sriprayoon2016 ER - TY - JOUR AU - Sung, J. J. Y. AU - Lai, J. Y. AU - Zeuzem, S. AU - Chow, W. C. AU - Heathcote, E. J. AU - Perrillo, R. P. PY - 2008 DA - 2008// TI - Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B JO - Journal of Hepatology. VL - 48 UR - https://doi.org/10.1016/j.jhep.2007.12.026 DO - 10.1016/j.jhep.2007.12.026 ID - Sung2008 ER - TY - JOUR AU - Tseng, K. -. C. AU - Chen, C. -. Y. AU - Tsai, H. -. W. AU - Chang, T. -. T. AU - Chuang, W. -. L. AU - Hsu, P. -. I. PY - 2014 DA - 2014// TI - Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study JO - Antivir Ther. VL - 19 UR - https://doi.org/10.3851/IMP2754 DO - 10.3851/IMP2754 ID - Tseng2014 ER - TY - JOUR AU - Xie, Q. AU - Zhou, H. AU - Bai, X. AU - Wu, S. AU - Chen, J. -. J. AU - Sheng, J. PY - 2014 DA - 2014// TI - A randomized, open-label clinical study of combined pegylated Interferon Alfa-2a (40KD) and Entecavir treatment for Hepatitis B “e” Antigen–Positive Chronic Hepatitis B JO - Clinical infectious diseases. VL - 59 UR - https://doi.org/10.1093/cid/ciu702 DO - 10.1093/cid/ciu702 ID - Xie2014 ER - TY - JOUR AU - Zhang, K. a. AU - Cao, H. o. n. g. AU - Liang, J. i. a. y. i. AU - Shu, X. i. n. AU - Sun, H. a. i. x. i. a. AU - Li, G. a. n. g. AU - Xu, Q. i. h. u. a. n. PY - 2016 DA - 2016// TI - CONSORT JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000004471 DO - 10.1097/MD.0000000000004471 ID - Zhang2016 ER - TY - JOUR AU - Bozkaya, H. AU - Yurdaydin, C. AU - Idilman, R. AU - Tuzun, A. AU - Cinar, K. AU - Erkan, O. PY - 2005 DA - 2005// TI - Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia JO - Antiviral Therapy. VL - 10 ID - Bozkaya2005 ER - TY - JOUR AU - Buti, M. AU - Gane, E. AU - Seto, W. K. AU - Chan, H. L. AU - Chuang, W. -. L. AU - Stepanova, T. PY - 2016 DA - 2016// TI - Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial JO - The Lancet Gastroenterology & Hepatology. VL - 1 UR - https://doi.org/10.1016/S2468-1253(16)30107-8 DO - 10.1016/S2468-1253(16)30107-8 ID - Buti2016 ER - TY - JOUR AU - Chan, H. L. Y. AU - Wang, H. AU - Niu, J. Q. AU - Chim, A. M. L. AU - Sung, J. J. Y. PY - 2007 DA - 2007// TI - Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial JO - Antiviral Therapy. VL - 12 ID - Chan2007 ER - TY - JOUR AU - Hadziyannis, S. J. AU - Tassopoulos, N. C. AU - Heathcote, E. J. AU - Chang, T. T. AU - Kitis, G. AU - Rizzetto, M. PY - 2003 DA - 2003// TI - Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B JO - N Engl J Med. VL - 348 UR - https://doi.org/10.1056/NEJMoa021812 DO - 10.1056/NEJMoa021812 ID - Hadziyannis2003 ER - TY - JOUR AU - Kaymakoglu, S. AU - Oguz, D. AU - Gur, G. AU - Gurel, S. AU - Tankurt, E. AU - Ersoz, G. PY - 2007 DA - 2007// TI - Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B JO - Antimicrob Agents Chemother. VL - 51 UR - https://doi.org/10.1128/AAC.00088-07 DO - 10.1128/AAC.00088-07 ID - Kaymakoglu2007 ER - TY - JOUR AU - Lai, C. -. L. AU - Shouval, D. AU - Lok, A. S. AU - Chang, T. -. T. AU - Cheinquer, H. AU - Goodman, Z. PY - 2006 DA - 2006// TI - Entecavir versus Lamivudine for patients with HBeAg-negative chronic hepatitis B JO - New England Journal of Medicine. VL - 354 UR - https://doi.org/10.1056/NEJMoa051287 DO - 10.1056/NEJMoa051287 ID - Lai2006 ER - TY - JOUR AU - Lampertico, P. AU - Vigano, M. AU - Costanzo, G. G. AU - Sagnelli, E. AU - Fasano, M. AU - Marco, V. PY - 2013 DA - 2013// TI - Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B JO - Gut. VL - 62 UR - https://doi.org/10.1136/gutjnl-2011-301430 DO - 10.1136/gutjnl-2011-301430 ID - Lampertico2013 ER - TY - JOUR AU - Lee, K. S. AU - Kweon, Y. -. O. AU - Um, S. -. H. AU - Kim, B. -. H. AU - Lim, Y. S. AU - Paik, S. W. PY - 2017 DA - 2017// TI - Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B JO - Clinical and molecular hepatology. VL - 23 UR - https://doi.org/10.3350/cmh.2016.0040 DO - 10.3350/cmh.2016.0040 ID - Lee2017 ER - TY - JOUR AU - Marcellin, P. AU - Lau, G. K. AU - Bonino, F. AU - Farci, P. AU - Hadziyannis, S. AU - Jin, R. PY - 2004 DA - 2004// TI - Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B JO - N Engl J Med. VL - 351 UR - https://doi.org/10.1056/NEJMoa040431 DO - 10.1056/NEJMoa040431 ID - Marcellin2004 ER - TY - JOUR AU - Papadopoulos, V. P. AU - Chrysagis, D. N. AU - Protopapas, A. N. AU - Goulis, I. G. AU - Dimitriadis, G. T. AU - Mimidis, K. P. PY - 2009 DA - 2009// TI - Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with hbeag-negative chronic hepatitis b: a randomised study JO - Medical Science Monitor. VL - 15 ID - Papadopoulos2009 ER - TY - JOUR AU - Piccolo, P. AU - Lenci, I. AU - Demelia, L. AU - Bandiera, F. AU - Piras, M. R. AU - Antonucci, G. PY - 2009 DA - 2009// TI - A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B JO - Antivir Ther. VL - 14 UR - https://doi.org/10.3851/IMP1466 DO - 10.3851/IMP1466 ID - Piccolo2009 ER - TY - JOUR AU - Tangkijvanich, P. AU - Chittmittraprap, S. AU - Poovorawan, K. AU - Limothai, U. AU - Khlaiphuengsin, A. AU - Chuaypen, N. PY - 2016 DA - 2016// TI - A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response JO - Journal of viral hepatitis. VL - 23 UR - https://doi.org/10.1111/jvh.12467 DO - 10.1111/jvh.12467 ID - Tangkijvanich2016 ER - TY - JOUR AU - Tassopoulos, N. C. AU - Volpes, R. AU - Pastore, G. AU - Heathcote, J. AU - Buti, M. AU - Goldin, R. D. PY - 1999 DA - 1999// TI - Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B JO - Lamivudine Precore Mutant Study Group. Hepatology. VL - 29 ID - Tassopoulos1999 ER - TY - JOUR AU - Hou, J. AU - Gao, Z. AU - Xie, Q. AU - Zhang, J. AU - Sheng, J. AU - Cheng, J. PY - 2015 DA - 2015// TI - Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial JO - Journal of viral hepatitis. VL - 22 UR - https://doi.org/10.1111/jvh.12313 DO - 10.1111/jvh.12313 ID - Hou2015 ER - TY - JOUR AU - Jia, J. D. AU - Hou, J. L. AU - Yin, Y. K. AU - Tan, D. M. AU - Xu, D. Z. AU - Niu, J. Q. PY - 2014 DA - 2014// TI - Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients JO - Hepatology International. VL - 8 UR - https://doi.org/10.1007/s12072-013-9488-2 DO - 10.1007/s12072-013-9488-2 ID - Jia2014 ER - TY - JOUR AU - Liaw, Y. F. AU - Gane, E. AU - Leung, N. AU - Zeuzem, S. AU - Wang, Y. AU - Lai, C. L. PY - 2009 DA - 2009// TI - 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B JO - Gastroenterology. VL - 136 UR - https://doi.org/10.1053/j.gastro.2008.10.026 DO - 10.1053/j.gastro.2008.10.026 ID - Liaw2009 ER - TY - JOUR AU - Lok, A. S. AU - Trinh, H. AU - Carosi, G. AU - Akarca, U. S. AU - Gadano, A. AU - Habersetzer, F. PY - 2012 DA - 2012// TI - Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B JO - Gastroenterology VL - 143 UR - https://doi.org/10.1053/j.gastro.2012.05.037 DO - 10.1053/j.gastro.2012.05.037 ID - Lok2012 ER - TY - JOUR AU - Marcellin, P. AU - Heathcote, E. J. AU - Buti, M. AU - Gane, E. AU - Man, R. A. AU - Krastev, Z. PY - 2008 DA - 2008// TI - Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B JO - N Engl J Med. VL - 359 UR - https://doi.org/10.1056/NEJMoa0802878 DO - 10.1056/NEJMoa0802878 ID - Marcellin2008 ER - TY - JOUR AU - Yao, G. B. AU - Chen, C. W. AU - Lu, W. L. AU - Ren, H. AU - Tan, D. M. AU - Wang, Y. M. PY - 2007 DA - 2007// TI - Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China JO - Hepatology International. VL - 1 UR - https://doi.org/10.1007/s12072-007-9009-2 DO - 10.1007/s12072-007-9009-2 ID - Yao2007 ER - TY - JOUR AU - Mbuagbaw, L. AU - Rochwerg, B. AU - Jaeschke, R. AU - Heels-Andsell, D. AU - Alhazzani, W. AU - Thabane, L. PY - 2017 DA - 2017// TI - Approaches to interpreting and choosing the best treatments in network meta-analyses JO - Systematic Reviews. VL - 6 UR - https://doi.org/10.1186/s13643-017-0473-z DO - 10.1186/s13643-017-0473-z ID - Mbuagbaw2017 ER - TY - JOUR AU - Chan, H. L. -. Y. AU - Buti, M. AU - Flisiak, R. AU - Ryder, S. AU - Streinu-Cercel, A. AU - Flaherty, J. F. PY - 2018 DA - 2018// TI - IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF) JO - Gut VL - 67 ID - Chan2018 ER - TY - JOUR AU - Agarwal, K. AU - Brunetto, M. AU - Seto, W. K. AU - Lim, Y. -. S. AU - Fung, S. AU - Marcellin, P. PY - 2018 DA - 2018// TI - 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection JO - Journal of Hepatology. VL - 68 UR - https://doi.org/10.1016/j.jhep.2017.11.039 DO - 10.1016/j.jhep.2017.11.039 ID - Agarwal2018 ER - TY - JOUR AU - Ogawa, E. AU - Furusyo, N. AU - Nguyen, M. H. PY - 2017 DA - 2017// TI - Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy JO - Drug Design, Development and Therapy. VL - 11 UR - https://doi.org/10.2147/DDDT.S126742 DO - 10.2147/DDDT.S126742 ID - Ogawa2017 ER - TY - JOUR AU - DeJesus, E. AU - Haas, B. AU - Segal-Maurer, S. AU - Ramgopal, M. N. AU - Mills, A. AU - Margot, N. PY - 2018 DA - 2018// TI - Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment JO - AIDS Research and Human Retroviruses. VL - 34 UR - https://doi.org/10.1089/aid.2017.0203 DO - 10.1089/aid.2017.0203 ID - DeJesus2018 ER - TY - JOUR AU - Ray, A. S. AU - Fordyce, M. W. AU - Hitchcock, M. J. M. PY - 2016 DA - 2016// TI - Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus JO - Antiviral Research. VL - 125 UR - https://doi.org/10.1016/j.antiviral.2015.11.009 DO - 10.1016/j.antiviral.2015.11.009 ID - Ray2016 ER - TY - JOUR AU - Chon, Y. E. AU - Kim, S. U. AU - Lee, C. K. AU - Heo, J. AU - Kim, J. K. AU - Yoon, K. T. PY - 2011 DA - 2011// TI - Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B JO - Antiviral Therapy. VL - 16 UR - https://doi.org/10.3851/IMP1772 DO - 10.3851/IMP1772 ID - Chon2011 ER - TY - BOOK AU - Dusheiko, G. AU - Lim, J. AU - Liou, I. AU - Tafazzoli, A. AU - Deniz, B. AU - Thibault, S. -. L. C. PY - 2017 DA - 2017// TI - Cost-effectiveness analysis of first-line administration of tenofoviR alafenamide (TAF), a novel nucleotide Reverse transcriptase inhibitor (NRTI), for the management of chronic hepatitis B (CHB) In the United States (US). Value in health PB - Elsevier Science INC CY - New York ID - Dusheiko2017 ER - TY - JOUR AU - Terrault, N. A. AU - Bzowej, N. H. AU - Chang, K. M. AU - Hwang, J. P. AU - Jonas, M. M. AU - Murad, M. H. PY - 2016 DA - 2016// TI - AASLD guidelines for treatment of chronic hepatitis B JO - Hepatology. VL - 63 UR - https://doi.org/10.1002/hep.28156 DO - 10.1002/hep.28156 ID - Terrault2016 ER - TY - STD TI - Organization WH. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: Mar-15: World Health Organization; 2015. ID - ref73 ER - TY - BOOK AU - Smith, M. PY - 2012 DA - 2012// TI - Class Update: Antivirals for Hepatitis B ID - Smith2012 ER - TY - JOUR AU - Kayaaslan, B. AU - Guner, R. PY - 2017 DA - 2017// TI - Adverse effects of oral antiviral therapy in chronic hepatitis B JO - World Journal of Hepatology. VL - 9 UR - https://doi.org/10.4254/wjh.v9.i5.227 DO - 10.4254/wjh.v9.i5.227 ID - Kayaaslan2017 ER - TY - JOUR AU - Woo, A. S. J. AU - Kwok, R. AU - Ahmed, T. PY - 2017 DA - 2017// TI - Alpha-interferon treatment in hepatitis B JO - Annals of Translational Medicine. VL - 5 UR - https://doi.org/10.21037/atm.2017.03.69 DO - 10.21037/atm.2017.03.69 ID - Woo2017 ER - TY - JOUR AU - Rijckborst, V. AU - Sonneveld, M. J. AU - Janssen, H. PY - 2011 DA - 2011// TI - chronic hepatitis B–anti-viral or immunomodulatory therapy? JO - Alimentary pharmacology & therapeutics. VL - 33 UR - https://doi.org/10.1111/j.1365-2036.2010.04555.x DO - 10.1111/j.1365-2036.2010.04555.x ID - Rijckborst2011 ER - TY - JOUR AU - Negro, F. PY - 2010 DA - 2010// TI - Adverse effects of drugs in the treatment of viral hepatitis JO - Best Practice & Research Clinical Gastroenterology. VL - 24 UR - https://doi.org/10.1016/j.bpg.2009.10.012 DO - 10.1016/j.bpg.2009.10.012 ID - Negro2010 ER - TY - JOUR AU - Dienstag, J. L. PY - 2009 DA - 2009// TI - Benefits and risks of nucleoside analog therapy for hepatitis B JO - Hepatology. VL - 49 UR - https://doi.org/10.1002/hep.22920 DO - 10.1002/hep.22920 ID - Dienstag2009 ER - TY - JOUR AU - Buster, E. H. AU - Hansen, B. E. AU - Lau, G. K. AU - Piratvisuth, T. AU - Zeuzem, S. AU - Steyerberg, E. W. PY - 2009 DA - 2009// TI - Factors that predict response of patients with hepatitis B e antigen–Positive chronic hepatitis B to peginterferon-alfa JO - Gastroenterology. VL - 137 UR - https://doi.org/10.1053/j.gastro.2009.08.061 DO - 10.1053/j.gastro.2009.08.061 ID - Buster2009 ER - TY - JOUR AU - Arends, P. AU - Sonneveld, M. J. AU - Janssen, H. L. PY - 2013 DA - 2013// TI - Hepatitis B virus treatment: which patients should be treated with interferon? JO - Clinical Liver Disease. VL - 2 UR - https://doi.org/10.1002/cld.152 DO - 10.1002/cld.152 ID - Arends2013 ER - TY - JOUR AU - Su, T. -. H. AU - Liu, C. -. J. PY - 2017 DA - 2017// TI - Combination therapy for chronic hepatitis B: current updates and perspectives JO - Gut and liver. VL - 11 UR - https://doi.org/10.5009/gnl16215 DO - 10.5009/gnl16215 ID - Su2017 ER - TY - JOUR AU - Chen, S. AU - Zhang, W. PY - 2015 DA - 2015// TI - HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos (t) ide analogues:“Switch-to” or “add-on” PegIFN alfa, that is the question JO - Journal of hepatology. VL - 62 UR - https://doi.org/10.1016/j.jhep.2014.08.056 DO - 10.1016/j.jhep.2014.08.056 ID - Chen2015 ER - TY - JOUR AU - Terrault, N. A. AU - Lok, A. S. AU - McMahon, B. J. AU - Chang, K. M. AU - Hwang, J. P. AU - Jonas, M. M. PY - 2018 DA - 2018// TI - Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance JO - Hepatology. VL - 67 UR - https://doi.org/10.1002/hep.29800 DO - 10.1002/hep.29800 ID - Terrault2018 ER - TY - JOUR AU - Govan, L. AU - Wu, O. AU - Xin, Y. AU - Hutchinson, S. J. AU - Hawkins, N. PY - 2015 DA - 2015// TI - Comparative effectiveness of antiviral treatment for hepatitis B: A systematic review and Bayesian network meta-analysis JO - European Journal of Gastroenterology and Hepatology. VL - 27 UR - https://doi.org/10.1097/MEG.0000000000000376 DO - 10.1097/MEG.0000000000000376 ID - Govan2015 ER - TY - JOUR AU - Liang, X. AU - Fan, R. AU - Sun, J. AU - Shaikh, J. AU - Taneja, A. AU - Gupta, S. PY - 2016 DA - 2016// TI - Effect of telbivudine versus other nucleos (t) ide analogs on HBeAg seroconversion and other outcomes in patients with chronic hepatitis B: a network meta-analysis JO - Advances in therapy. VL - 33 UR - https://doi.org/10.1007/s12325-016-0305-x DO - 10.1007/s12325-016-0305-x ID - Liang2016 ER - TY - JOUR AU - Xing, T. AU - Xu, H. AU - Cao, L. AU - Ye, M. PY - 2017 DA - 2017// TI - HBeAg seroconversion in HBeAg-positive chronic hepatitis B Patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis JO - PLOS ONE. VL - 12 UR - https://doi.org/10.1371/journal.pone.0169444 DO - 10.1371/journal.pone.0169444 ID - Xing2017 ER - TY - JOUR AU - Zoulim, F. AU - Białkowska-Warzecha, J. AU - Diculescu, M. M. AU - Goldis, A. E. AU - Heyne, R. AU - Mach, T. PY - 2016 DA - 2016// TI - Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure JO - Hepatology international. VL - 10 UR - https://doi.org/10.1007/s12072-016-9737-2 DO - 10.1007/s12072-016-9737-2 ID - Zoulim2016 ER - TY - JOUR AU - Lim, Y. -. S. PY - 2017 DA - 2017// TI - Management of Antiviral Resistance in Chronic Hepatitis B JO - Gut and Liver. VL - 11 UR - https://doi.org/10.5009/gnl15562 DO - 10.5009/gnl15562 ID - Lim2017 ER - TY - JOUR AU - Lin, C. -. L. AU - Kao, J. -. H. PY - 2013 DA - 2013// TI - Hepatitis B viral factors and treatment responses in chronic hepatitis B JO - Journal of the Formosan Medical Association. VL - 112 UR - https://doi.org/10.1016/j.jfma.2013.02.001 DO - 10.1016/j.jfma.2013.02.001 ID - Lin2013 ER - TY - JOUR AU - Wang, Y. -. C. AU - Yang, S. -. S. AU - Su, C. -. W. AU - Wang, Y. -. J. AU - Lee, K. -. C. AU - Huo, T. -. I. PY - 2016 DA - 2016// TI - Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis JO - Scientific Reports. VL - 6 UR - https://doi.org/10.1038/srep29605 DO - 10.1038/srep29605 ID - Wang2016 ER - TY - JOUR AU - Cho, J. -. Y. AU - Sohn, W. AU - Sinn, D. -. H. AU - Gwak, G. -. Y. AU - Paik, Y. -. H. AU - Choi, M. S. PY - 2017 DA - 2017// TI - Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response JO - The Korean journal of internal medicine. VL - 32 UR - https://doi.org/10.3904/kjim.2016.096 DO - 10.3904/kjim.2016.096 ID - Cho2017 ER - TY - JOUR AU - Brunetto, M. R. AU - Marcellin, P. AU - Cherubini, B. AU - Yurdaydin, C. AU - Farci, P. AU - Hadziyannis, S. J. PY - 2013 DA - 2013// TI - Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype JO - Journal of hepatology. VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.07.017 DO - 10.1016/j.jhep.2013.07.017 ID - Brunetto2013 ER - TY - JOUR AU - Enomoto, M. AU - Tamori, A. AU - Nishiguchi, S. PY - 2006 DA - 2006// TI - Hepatitis B virus genotypes and response to antiviral therapy JO - Clinical laboratory. VL - 52 ID - Enomoto2006 ER - TY - JOUR AU - Li, T. AU - Puhan, M. A. AU - Vedula, S. S. AU - Singh, S. AU - Dickersin, K. PY - 2011 DA - 2011// TI - Network meta-analysis-highly attractive but more methodological research is needed JO - BMC medicine. VL - 9 UR - https://doi.org/10.1186/1741-7015-9-79 DO - 10.1186/1741-7015-9-79 ID - Li2011 ER - TY - JOUR AU - Mealing, S. AU - Ghement, I. AU - Hawkins, N. AU - Scott, D. A. AU - Lescrauwaet, B. AU - Watt, M. PY - 2014 DA - 2014// TI - The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis JO - Systematic reviews. VL - 3 UR - https://doi.org/10.1186/2046-4053-3-21 DO - 10.1186/2046-4053-3-21 ID - Mealing2014 ER - TY - JOUR AU - Soriano, V. AU - Barreiro, P. AU - Benitez, L. AU - Peña, J. M. AU - Mendoza, C. PY - 2017 DA - 2017// TI - New antivirals for the treatment of chronic hepatitis B JO - Expert opinion on investigational drugs. VL - 26 UR - https://doi.org/10.1080/13543784.2017.1333105 DO - 10.1080/13543784.2017.1333105 ID - Soriano2017 ER - TY - JOUR AU - Emery, J. S. AU - Feld, J. J. PY - 2017 DA - 2017// TI - Treatment of hepatitis B virus with combination therapy now and in the future JO - Best Practice & Research Clinical Gastroenterology. VL - 31 UR - https://doi.org/10.1016/j.bpg.2017.04.007 DO - 10.1016/j.bpg.2017.04.007 ID - Emery2017 ER - TY - JOUR AU - Gane, E. J. PY - 2017 DA - 2017// TI - Future anti-HBV strategies JO - Liver International. VL - 37 UR - https://doi.org/10.1111/liv.13304 DO - 10.1111/liv.13304 ID - Gane2017 ER - TY - JOUR AU - Tseng, T. -. C. AU - Kao, J. -. H. PY - 2017 DA - 2017// TI - Elimination of hepatitis B: is it a mission possible? JO - BMC medicine. VL - 15 UR - https://doi.org/10.1186/s12916-017-0820-x DO - 10.1186/s12916-017-0820-x ID - Tseng2017 ER -